论文部分内容阅读
背景与目的:肝细胞癌(hepatocellular carcinoma,HCC)是一种具有高度侵袭、转移性的常见恶性肿瘤,预后极差。因此,研究肝癌侵袭的机制,寻找有效的干预靶点显得尤为重要。一些研究提示分泌型聚集素(secreted Clusterin,sCLU)和高尔基体糖蛋白73(Golgi glycoprotein 73,GP73)在肿瘤发生、发展及侵袭、转移过程中起重要作用,且两者具有结构和功能上的相似性。本研究旨在探讨GP73和sCLU在HCC中的表达及其与临床病理特征和预后之间的关系。方法:收集新疆医科大学第一附属医院75例HCC患者癌组织及癌旁正常肝组织标本,采用免疫组化(EnVision二步法)检测HCC组织中GP73、sCLU的表达水平;并与癌旁正常肝组织相比较;Spearman等级相关分析GP73和sCLU在肝癌中表达的关系;研究GP73和sCLU表达水平与HCC临床病理特征及预后的关系。结果:GP73和sCLU在HCC中阳性表达率分别为72%和88%,癌旁正常肝组织的阳性表达率均为4%。GP73在HCC和正常肝组织中阳性表达差异有统计学意义(χ2=73.60,P<0.05)。sCLU在HCC和正常肝组织中阳性表达差异有统计学意义(χ2=207.94,P<0.05);Spearman等级相关分析提示,HCC组织中,GP73和sCLU蛋白表达呈正相关(r=0.405,P<0.05);GP73和sCLU在HCC中表达水平与肿瘤的Edmondson病理分级、TNM分期及血管侵犯相关(P<0.05),而与患者的性别、年龄、HBsAg、合并肝硬化、AFP值、门静脉癌栓、肿瘤数目无相关性(P>0.05);GP73表达与患者生存期有关,而sCLU表达与患者生存期无关。结论:GP73和sCLU在肝癌中有较高的阳性率,且GP73和sCLU表达呈正相关,GP73和sCLU可能与HCC的侵袭性等生物行为密切相关,检测其表达将有助于评价患者预后。
BACKGROUND & OBJECTIVE: Hepatocellular carcinoma (HCC) is a highly malignant and metastatic common malignant tumor with a very poor prognosis. Therefore, it is particularly important to study the mechanism of liver cancer invasion and find effective intervention targets. Some studies suggest that secreted clusterin (sCLU) and Golgi glycoprotein 73 (GP73) play an important role in tumorigenesis, development, invasion and metastasis, and both have structural and functional roles. Similarity. The purpose of this study was to investigate the expression of GP73 and sCLU in HCC and its relationship with clinicopathological features and prognosis. METHODS: A total of 75 specimens of HCC patients and adjacent normal liver tissues were collected from the First Affiliated Hospital of Xinjiang Medical University. EnVision immunohistochemistry (EnVision two-step method) was used to detect the expression of GP73 and sCLU in HCC tissues. Comparison of liver tissue; Spearman rank correlation analysis of the expression of GP73 and sCLU in hepatocellular carcinoma; The relationship between GP73 and sCLU expression levels and clinicopathological features and prognosis of HCC. RESULTS: The positive expression rates of GP73 and sCLU in HCC were 72% and 88%, respectively, and the positive rate of para-tumor normal liver tissue was 4%. The positive expression of GP73 in HCC and normal liver tissues was statistically significant (χ2=73.60, P<0.05). The positive expression of sCLU in HCC and normal liver tissues was statistically significant (χ2=207.94, P<0.05). Spearman rank correlation analysis suggested that there was a positive correlation between GP73 and sCLU protein expression in HCC tissues (r=0.405, P<0.05). The expression levels of GP73 and sCLU in HCC were correlated with tumor Edmondson pathological grade, TNM stage, and vascular invasion (P<0.05), but were related to the patient’s gender, age, HBsAg, cirrhosis, AFP, portal vein tumor thrombus, There was no correlation between the number of tumors (P>0.05). The expression of GP73 was related to the survival time of patients. The expression of sCLU was not related to the survival time of patients. Conclusion: GP73 and sCLU are highly positive in HCC, and GP73 and sCLU are positively correlated. GP73 and sCLU may be closely related to biological behavior such as invasiveness of HCC. Detecting the expression of GP73 and sCLU will help evaluate the prognosis of patients.